Nemolizumab

SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company’s deep, innovative pipeline of candidates. “Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “Her expertise includes a proven track record of building and managing global commercial organizations, driving successful global launches of breakthrough therapies and bringing innovative medicines to market. I am thrilled to welcome Isabel into this pivotal commercial leadership role as we seek to deliver a new generation of therapy for acromegaly and transform the lives of large numbers of people impacted by other endocrine-related conditions.” “I feel so fortunate to join Crinetics at this time,” said Ms. Kalofonos. “Building highly effective commercial teams to launch transformative products has been the focus of my career. I look forward to bringing my experience to a company like Crinetics that is well-positioned to be a leader in endocrinology and has the potential to make a meaningful advancement for the acromegaly community and endocrine disorders. I look forward to leading the company’s strategy for the first potential commercial launch, building a best-in-class commercial team and continuing to build value for products in the pipeline.” Ms. Kalofonos joins Crinetics with more than 20 years of global experience in the pharmaceutical and biotech industry, including roles leading business and commercial units and expertise in marketing, new product planning, market access and pricing. She previously served as Senior Vice President and Chief Commercial Officer at ImmunoGen (acquired by Abbvie), where she was responsible for leading the successful launch of ELAHERE (mirvetuximab), a treatment for ovarian cancer and for overseeing the commercial strategy for the pipeline of antibody-drug conjugates in oncology indications. Ms. Kalofonos led the sales, marketing, market access and commercial operations teams in the U.S., as well as international launch preparation. Prior to ImmunoGen, Ms. Kalofonos worked at Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for NEMLUVIO (nemolizumab), a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise, a $2.5-billion business. In this role, she oversaw the global blockbuster launch of TAKHZYRO (lanadelumab-flyo). Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas, including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Ms. Kalofonos holds an MBA in entrepreneurship and marketing from Babson College and an undergraduate degree in industrial engineering from Pontificia Universidad Javeriana. On January 10, 2025, the Company expects to grant Ms. Kalofonos a stock option to purchase 100,000 shares of common stock under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”), 25 percent of which will vest on December 16, 2025, and the remainder will vest in 36 equal monthly installments thereafter. The stock option will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on January 10, 2025. The stock option will be subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the respective grant. The stock option will be granted as an inducement material to Ms. Kalofonos entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the, the therapeutic potential and clinical benefits or safety profile of paltusotine for patients with acromegaly, the plans and timelines for the commercial launch paltusotine for acromegaly, if approved, and the potential of our other research, discovery, and clinical trial programs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the Company’s product candidates that may limit their development, regulatory approval and/or commercialization; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; and Crinetics’ drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023, and its Quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com(858) 345-6340 Media:Natalie BadilloHead of Corporate Communicationsnbadillo@crinetics.com(858) 345-6075

Plus, news about Foghorn Therapeutics, Incyte, BioNTech, Galderma, Basilea, Innovia, Pharming, bit.bio, Promise Bio, Outlook Therapeutics and Trevi Therapeutics: Candid Therapeutics’ trio of T cell engager deals: The company is paying up to $320 million in upfront and milestones to Nona Biosciences to develop next-generation T cell engagers. It’s also partnering with Ab Studio to discover T cell engagers that treat autoimmune diseases. No terms were disclosed. And, in its third announcement, Candid also said Monday that it will spend up to $1 billion in a deal with EpimAb Biotherapeutics that also aims to develop T cell engagers in the autoimmune category. — Jaimy Lee PepGen’s Duchenne trial put on hold: The biotech said the FDA put its CONNECT2-EDO51 study on hold. It’s a Phase 2 trial assessing multiple ascending doses in patients with Duchenne muscular dystrophy. Its stock $PEPG sank 28% on Monday morning. — Jaimy Lee Foghorn to drop AML candidate: The company is stopping work on an experimental drug for acute myeloid leukemia called FHD-286, and it’s seeking a potential partner for the drug. Foghorn said that it saw responses to the drug in a Phase 1 study, but “the observed response rate did not meet the company’s threshold to continue development by Foghorn alone.” — Lei Lei Wu Incyte stops developing anemia drug for patients with myelofibrosis: During an investor day last week, the company said zilurgisertib “does not significantly improve anemia in patients with myelofibrosis,” and it had halted work on the drug. — Katherine Lewin BioNTech, OncoC4’s partial clinical hold is lifted: The FDA gave the go-ahead to the partners to continue a Phase 3 lung cancer trial of an anti-CTLA-4 antibody called gotistobart, but only in a subset of patients, BioNTech disclosed Friday. In October, the study was put on partial clinical hold due to a “a possible variance in results between the squamous and non-squamous NSCLC patient populations.” The study will now only enroll squamous NSCLC patients. — Lei Lei Wu FDA approves Galderma’s Nemluvio in moderate-to-severe atopic dermatitis: The drug is now approved to treat patients 12 years and older. Nemluvio is also approved for prurigo nodularis, another chronic skin condition. According to Galderma, Nemluvio is the first approved monoclonal antibody that specifically targets the cytokine IL-31, which causes the itching and inflammation associated with the disease. Its Swiss-listed shares $GALD were up about 7% on Monday. — Katherine Lewin Basilea inks deal with Innoviva to market antibiotic: Innoviva is paying Basilea $4 million upfront and up to $223 million in sales milestones, plus royalties, to commercialize Zevtera in the US. The anti-MRSA antibiotic received FDA approval in April. — Jaimy Lee Pharming’s $66M offer to buy Abliva: Pharming wants to buy the Swedish company, which is developing a treatment for mitochondrial disease. The lead asset is currently in a pivotal trial. — Jaimy Lee Bit.bio raises $30M for cell therapy pipeline: The biotech plans to use the proceeds to invest in new tools for drug discovery and research. The fundraise was led by M&G Investments, with support from backers including ARCH Venture Partners and Milky Way. The company unveiled its lead program , which is designed to regenerate the liver, a year ago. — Ayisha Sharma Israeli biotech secures $8.3M in seed funding: Promise Bio expects to use the cash to develop a computational platform powered by AI and epiproteomics that could help predict patient responses to treatment. The round was led by Awz Ventures. AION Labs also invested. — Ayisha Sharma Outlook to cut 23% of its workforce: The company underwent a strategic review as it aims to shore up funds to support the launch of its new wet AMD treatment, which was approved in Europe and the UK this year. The company plans to submit its formulation of bevacizumab to the FDA in the first three months of next year after receiving a complete response letter last year. Outlook had 24 full-time employees, as of September 2023.— Jaimy Lee Trevi is selling 12.5 million shares at $4.00 apiece to raise $50 million. — Jaimy Lee